These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 33956869)

  • 1. Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia.
    Megasari NLA; Utsumi T; Yamani LN; Juniastuti ; Gunawan E; Furukawa K; Nishimura M; Lusida MI; Mori Y
    PLoS One; 2021; 16(5):e0251234. PubMed ID: 33956869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroprevalence of SARS-CoV-2 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java, Indonesia.
    Megasari NLA; Yamani LN; Juniastuti J; Lusida MI; Mori Y
    PeerJ; 2023; 11():e16142. PubMed ID: 37780375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of SARS-COV-2 positivity in 516 German intensive care and emergency physicians studied by seroprevalence of antibodies National Covid Survey Germany (NAT-COV-SURV).
    Kindgen-Milles D; Brandenburger T; Braun JFW; Cleff C; Moussazadeh K; Mrosewski I; Timm J; Wetzchewald D
    PLoS One; 2021; 16(4):e0248813. PubMed ID: 33831032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
    Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serological tests for SARS-CoV-2 in a health workers population in Nouakchott-Mauritania].
    Salem MLO; Sidiya MAMM; Eibih ABA; Maouloud MM; Ngaide BH; Dedy L; Hamza LM; Yacoub F
    Pan Afr Med J; 2021; 38():55. PubMed ID: 33854684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of COVID-19 Virus Infection in Semnan province.
    Jandaghi E; Hemati M; Mohammadlou M; Jandaghi J; Mirmohammadkhani M; Danaei N; Kokhaei P
    Iran J Immunol; 2021 Mar; 18(1):74-81. PubMed ID: 33787516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.
    Yokoyama R; Kurano M; Morita Y; Shimura T; Nakano Y; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    PLoS One; 2021; 16(3):e0247711. PubMed ID: 33661990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points to IgM as the Achilles heel.
    Mboumba Bouassa RS; Péré H; Tonen-Wolyec S; Longo JD; Moussa S; Mbopi-Keou FX; Mossoro-Kpinde CD; Grésenguet G; Veyer D; Bélec L
    J Med Virol; 2021 Apr; 93(4):2196-2203. PubMed ID: 33107601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.
    Shu H; Wang S; Ruan S; Wang Y; Zhang J; Yuan Y; Liu H; Wu Y; Li R; Pan S; Ouyang Y; Yuan S; Zhou P; Shang Y
    Virol Sin; 2020 Dec; 35(6):744-751. PubMed ID: 32720214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran.
    Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M
    Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative SARS-CoV-2 Antibody Screening of Healthcare Workers in the Southern Part of Kyoto City During the COVID-19 Pre-pandemic Period.
    Fujita K; Kada S; Kanai O; Hata H; Odagaki T; Satoh-Asahara N; Tagami T; Yasoda A
    Front Public Health; 2020; 8():595348. PubMed ID: 33365297
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-SARS-CoV-2 IgG antibody response among Indian COVID-19 patients using β-propiolactone-inactivated, whole virus-based indirect ELISA.
    Kulkarni R; Patil HP; Palkar S; Lalwani S; Mishra AC; Arankalle V
    J Virol Methods; 2021 Jan; 287():113996. PubMed ID: 33126149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of COVID-19 IgG Antibodies in a Cohort of Municipal First Responders.
    McGuire SS; Klassen AB; Heywood J; Sztajnkrycer MD
    Prehosp Disaster Med; 2021 Apr; 36(2):131-134. PubMed ID: 33397545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Seroprevalence in Healthcare Workers of Kaunas Hospitals during the First Wave of the COVID-19 Pandemic.
    Pereckaitė L; Dambrauskienė A; Urbonienė D; Sadauskas S; Petrikonis K; Naudžiūnas A; Vitkauskienė A
    Medicina (Kaunas); 2021 Feb; 57(2):. PubMed ID: 33562085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.